Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Evening all
Hold a small position here & have traded the crazy volatility in recent weeks for Rum cash , however looks a very decent LT hold/buy with recent drilling RNS etc ,
so will keep my eyes watching with a bag of dry powder .
A Few numbers for anyone interested
( source - Ortex )
In the industrial gases sector, Helium One Global Ltd has recently outpaced its counterparts, with a notable increase of 294.9% over its peers in the last month.
The stock's price performance over the past week has seen a 13.05% uptick, while its Year-To-Date price change stands at an impressive 587.5%
. Additionally, Relative Strength Index (RSI) is registered at 71.35.
Stock on loan / shorts
3 million - approx £70k value - down 15k
Cost to borrow - 52
Dtc - 5.6
No flagged shorts to report
MCap - 75 million
Heavy volume in recent sessions
52 week high 10p
52 week low - 0.2p
Good luck all invested here in these volatile markets , however it does bring out the good , the bad & the ugly .
Evening most
Decent graft go into that post Mont , thumbs up .
Precious metals in demand & wars are expensive but obviously not without risk .
Noted many times -
Green Energy boom / precious metal world demand Vs War situation/ economic climate
Worth holding stock at current price imo .so I will do .
Runs & wait for the ass nibblers all Round
Afternoon all invested
Looking forward to another week for Hemo investors , had a lubrication of grog & a belly full of Sunday grub & ready for market action .
Whatever the market shenanigans on Friday ,
Hemo is Clinical on CAR T & underpinned by Prevail & pharmas will imo be queuing up for partnerships / licensing deals like a Whitby chippy on bank holiday .
Some toxic knackers on here today after some very genuine & sincere posts yesterday, simply no need dudes , Hemo are now in a great position , absorb & Enjoy .
Fetch the CAR T deals & grog
Popped up on Ortex - last night plenty of publicity is good ( I appreciate it’s similar info but to a new investor audience )
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
Stock House
10th Feb 18:36
FDA Consents to Phase I Trials of HEMO-CAR-T LONDON, UK/ ACCESSWIRE/ February 9, 2024/ Hemogenyx Pharmaceuticals plc is pleased to announce that it has been informed by the U.S.
Federal Food and Drug Administration ("FDA") that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML"). The FDA confirmed that the Company had addressed all issues identified in its prior clinical hold letter satisfactorily and consents to the Company proceeding with its Phase I clinical study of HEMO-CAR-T.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased with the FDA's decision to lift the clinical hold. We now look forward to accelerating clinical development of HEMO-CAR-T and to offering patients a potentially life-saving treatment. The removal of the clinical hold was made possible by the hard work and dedication of the entire Hemogenyx Pharmaceuticals team and its Board of Directors and advisors."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Fetch the CAR T Clinical Grog
Morning All
Great upward trend over last 4 months since Prevail got involved & since then now clinical on CAR T - the seas in front certainly look blue
As per recent trading update I posted from Ortex Friday
1 week increase 18%
2 week increase 40%
Hemo - has increased 90% compared to its biotech peers in last month
RSI at 75 shows strength
Volume 129 million 15 times above 3 month average
Stock price 90% up on year
& 3 month price graph since Prevail got involved showing strong uptrend & reflected in above figures & after Fridays Shenanigans with 129 million traded & quality RNS I would expect the north trajectory to continue over coming weeks .
Multi pronged science gaining traction for sure-
CAR T - unfolded & into clinical
CBR - cooking
CDX -cooking
All making superb progress & Prevail underpinning with pharmas deals / partnerships likely in the pipeline & soon .imo
Fetch the weekend Throat massager
Morning all invested
What a volatile week , however did bag a superb RNS all though not yet perhaps recognised by the markets .As Pawking has noted 130 million traded yesterday with every toxic trader & CFD fiddler on LSE turning up to milk the RNS udders ,
likely in both directions flipping the trades hence the toxicity on here most of the session .
Anyhow ,the RNS will sink in & no doubt another RNS with a forward clinical plan via Prevail in the pipeline .
Ortex update on trading -
Hemogenyx Pharmaceuticals (HEMO) has recently displayed remarkable volatility compared to its biotech peers,
surging 86.47% more in the last month.
Trading activity soared, with the last day's trading volume hitting 129,888,900 shares, dwarfing the three-month average by over fifteen-fold.
The company has also captured significant attention in the news and on social media in the past day.
Over the past week, HEMO has achieved an 8.36% price increase,
its Year-To-Date price change standing at 71.96%, accompanied by a notably high Relative Strength Index (RSI) of 73.75.
The Stock will re rate as more news lands & been a great start to 2024 for all invested
CAR T - Boiling
CDX & CBR - cooking
Fetch the Weekend Full English with all the trimmings including Black pudding mmmm…..
Gheko
Sorry for loss
A genuine heart felt post
unfortunately this hideous disease effects so many of us & our families & hopefully Hemo can bring a cure into the world saving many lives & parting the dark clouds of pain & suffering .
Evening All -
Generally on these boards & as noticed today
Unfortunately when a quality stock begins to bare fruit , you get the poisonous toads turning up with keyboard in one hand & small pecker in the other , green with envy & reeking of agenda
Greed brings the worst out in toxic human behaviour & plenty of examples on these chat forums for sure as seen today .
I am a dad & grandad & live on a boat , hence the nautical banter - some just don’t get it , it’s harmless humour while we all try to make a few bucks in these unforgiving markets .
Anyhow
Only the beginning for CAR T & Hemo investors - underpinned by Prevail
& in the background CBR & CD X still cooking
Fetch the finest weekend Grog
A few delayed kippers slapping on deck
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
09-Feb-24 16:15:31 4.011 400,000 Unknown* 3.81 4.10 16.04k O
09-Feb-24 09:31:04 4.81 1,000,000 Unknown* 3.81 4.10 48.10k O
09-Feb-24 09:27:00 5.14 967,788 Unknown* 3.81 4.10 49.74k O
09-Feb-24 08:31:43 4.5034 1,000,000 Unknown* 3.81 4.10 45.03k O
Price 4.10
Vol 126 million
Vwap 4.75
Auto vol 14 million
What a crazy days trading , investors got the clinical confirmation RNS &
Prevail underpinning
However finished flat after initial spike - Today’s crazy trading perhaps priced in RNS or just the way the market shenanigans unfold .
Next week , let’s see what occurs I’m off to get grogged up .
Hemo are Clinical on CAR T with Prevail underpinning period .
With CDX & CBR in the mix
Traders will do there thing as will MMs
Let’s see where the sp finishes today & over next week with Pharmas sniffing around with there cheque books
Fetch the CAR T throat massager I think a few need it
Guinness & all
Absolutely, thousands of delayed stock printed from earlier slapping on deck ,
Perhaps balancing trades after bonkers start this morn .
To note -
Vwap rising
Spread tightening
Let’s see what next hour brings & mms have there Friday fun
CAR T nailed for clinical
100 million volume reached
Vwap - 4.85
Auto vol 13 million
+41 + 11%
Expecting some large delayed kippers pm
Let’s see how the pm & weeks ahead pan out
100% + in last few weeks .
More importantly than the above - long term CAR T clinical nailed with Prevail underpinning
Friday clinical Grog for all invested
These bozo traders turn up late to the party & have to pay a premium in Hemo , Eua , etc & want to blame anyone but themselves for there poor choices
The info I post is from sources noted , try doing your own research & take responsibility for your own investment decisions ,
Pathetic human specimens for sure .
They spring up like Toxic blow up dolls in the back of Del boys van
Generally on these boards ..
Unfortunately when a quality stock begins to bag , you get the poisonous toads turning up with keyboard in one hand & small pecker in the other , green with envy & reeking of agenda
Greed brings the worst out in human behaviour & plenty on these chat forums for sure ,
I am a dad m grandad & live on a boat , hence the nautical banter - some just don’t get it , it’s harmless humour while we all try to make a few quid .
Only the beginning for CAR T & Hemo investors
With CBR & CD X still cooking
Fetch the finest Grog
Popped up on Ortex - words out on Hemo
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases
- US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia.
FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells.
Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.
Company says on Friday that the FDA has confirmed that all issues identified in its clinical hold letter have been satisfactorily addressed. FDA therefore consents to Hemogenyx proceeding with its phase 1 clinical study of Hemo-Car-T.
Chief Executive Officer Vladislav Sandler comments: "We are extremely pleased with the FDA's decision to lift the clinical hold. We now look forward to accelerating clinical development of Hemo-Car-T and to offering patients a potentially life-saving treatment."
Current stock price: 4.6 pence, up 16% on Friday morning
12-month change: 100% +
The word will be getting out there on Hemo science & subsequent stock re rate
Fetch the Grog